新闻源 财富源

2019年10月14日 星期一

誉衡药业(002437)公告正文

誉衡药业:2012年半年度报告摘要

公告日期:2012-08-18

           哈尔滨誉衡药业股份有限公司                                                       2012 年半年度报告摘要
           股票代码:002437                      股票简称:誉衡药业           公告编号:2012-048
                                  哈尔滨誉衡药业股份有限公司
                                        2012 年半年度报告摘要
                                                 一、重要提示
    本公司董事会、监事会及董事、监事、高级管理人员保证本报告所载资料不存在任何虚假记载、误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连带责任。
    所有董事均已出席了审议本次半年报的董事会会议。
    公司半年度财务报告未经会计师事务所审计。
    公司负责人朱吉满、主管会计工作负责人杨华蓉及会计机构负责人(会计主管人员)赵金宇声明:保证半年度报告中财务报告的真实、完整。
                                          二、公司基本情况(一)基本情况简介
    A 股简称                            誉衡药业
    A 股代码                            002437
    上市证券交易所                      深圳证券交易所
                                                     董事会秘书                        证券事务代表
    姓名                                于天巡                             刘畅
                                        黑龙江省哈尔滨市呼兰区利民经济技   北京市顺义区空港开发区 B 区裕华路
    联系地址
                                        术开发区燕京路 29 号               融慧园 28 号
    电话                                010-68002437                       010-68002437
    传真                                010-68002438-607                   010-68002438-607
    电子信箱                            yutianxun@gloria.cc                liuchang@gloria.cc(二)主要财务数据和指标1、主要会计数据和财务指标以前报告期财务报表是否发生了追溯调整□ 是 √ 否
                                              本报告期末             上年度期末           本报告期末比上年度期1
           哈尔滨誉衡药业股份有限公司                                                           2012 年半年度报告摘要
                                                                                                   末增减(%)
    总资产(元)                                 2,430,161,533.96       2,312,253,611.26                        5.1%
    归属于上市公司股东的所有者权益
                                                 2,245,944,075.22       2,168,090,717.47                       3.59%
    (元)
    股本(股)                                    280,000,000.00          280,000,000.00                          0%
    归属于上市公司股东的每股净资产(元
                                                             8.02                      7.74                    3.62%
    /股)
    资产负债率(%)                                         6.4%                     4.97%                     1.43%
                                                                                              本报告期比上年同期增
                                          报告期(1-6 月)              上年同期
                                                                                                      减(%)
    营业总收入(元)                              333,124,341.47          254,966,833.88                    30.65%
    营业利润(元)                                 94,434,390.49              76,308,713.26                 23.75%
    利润总额(元)                                 94,357,080.68              76,243,084.42                 23.76%
    归属于上市公司股东的净利润(元)               77,853,357.75              63,883,959.76                 21.87%
    归属于上市公司股东的扣除非经常性
                                                   66,361,104.10              63,941,384.99                    3.78%
    损益的净利润(元)
    基本每股收益(元/股)                                    0.28                      0.23                 21.74%
    稀释每股收益(元/股)                                    0.28                      0.23                 21.74%
    加权平均净资产收益率(%)                              3.53%                     3.02%                     0.51%
    扣除非经常性损益后的加权平均净资
                                                           3.01%                     3.02%                     -0.01%
    产收益率(%)
    经营活动产生的现金流量净额(元)              107,620,813.09              43,586,075.74                146.92%
    每股经营活动产生的现金流量净额(元
                                                             0.38                      0.16                 137.5%
    /股)报告期末公司前主要会计数据和财务指标的说明(如有追溯调整,请填写调整说明)本报告期内,营业总收入同比增长30.65%,营业利润同比增长23.75%,利润总额同比增长23.76%,归属于上市公司股东的净利润同比增长21.87%,净利润增长主要是本期营业收入增长、募集资金专户定期存款利息增长实现。本报告期内,经营活动产生的现金流量净额较上年同期增长146.92%,因销售增长销售回款增多。2、非经常性损益项目√ 适用 □ 不适用
                                                         年初到报告期末金额
                     非经常性损益项目                                                           说明
                                                               (元)
    非流动资产处置损益                                               2,025.19
    越权审批或无正式批准文件的税收返还、减免
    计入当期损益的政府补助(与企业业务密切相关,按
    照国家统一标准定额或定量享受的政府补助除外)
    计入当期损益的对非金融企业收取的资金占用费
    企业取得子公司、联营企业及合营企业的投资成本小
    于取得投资时应享有被投资单位可辨认净资产公允价
    值产生的收益
    非货币性资产交换损益
    委托他人投资或管理资产的损益
    因不可抗力因素,如遭受自然灾害而计提的各项资产
    减值准备
    债务重组损益2
           哈尔滨誉衡药业股份有限公司                                                      2012 年半年度报告摘要
    企业重组费用,如安置职工的支出、整合费用等
    交易价格显失公允的交易产生的超过公允价值部分的
    损益
    同一控制下企业合并产生的子公司期初至合并日的当
    期净损益
    与公司正常经营业务无关的或有事项产生的损益
    除同公司正常经营业务相关的有效套期保值业务外,
    持有交易性金融资产、交易性金融负债产生的公允价
    值变动损益,以及处置交易性金融资产、交易性金融
    负债和可供出售金融资产取得的投资收益
    单独进行减值测试的应收款项减值准备转回
    对外委托贷款取得的损益
    采用公允价值模式进行后续计量的投资性房地产公允
    价值变动产生的损益
    根据税收、会计等法律、法规的要求对当期损益进行
    一次性调整对当期损益的影响
    受托经营取得的托管费收入
    除上述各项之外的其他营业外收入和支出                         -79,335.00
                                                                              募集资金专户存款定期利息收入,理
    其他符合非经常性损益定义的损益项目                      13,542,904.07
                                                                              财产品取得收益
    少数股东权益影响额                                              210.00
    所得税影响额                                             -1,973,550.61
    合计                                                    11,492,253.65                    --3、同时按照国际会计准则与按中国会计准则披露的财务报告中净利润和净资产差异情况□ 适用 √ 不适用4、同时按照境外会计准则与按中国会计准则披露的财务报告中净利润和净资产差异情况□ 适用 √ 不适用
                                     三、股本变动及股东情况(一)股本变动情况表□ 适用 √ 不适用(二)前 10 名股东、前 10 名无限售条件股东/流通股股东持股情况表前 10 名股东、前 10 名无限售条件股东持股情况表
    股东总数                                                                                              16,115
    前十名股东持股情况
      股东名称(全称)         股东性质      持股比   持股总数       持有有限售          质押或冻结情况3
           哈尔滨誉衡药业股份有限公司                                                         2012 年半年度报告摘要
                                               例(%)                     条件股份数
                                                                                         股份状态          数量
                                                                             量
    哈尔滨恒世达昌科技有     境内非国有法
                                               44.63%      124,950,000   124,950,000   质押                17,600,000
                   限公司               人
               YU HENG
         INTERNATIONAL
                                   境外法人      21%        58,800,000    58,800,000
           INVESTMENTS
           CORPORATION
    ORIENTAL KEYSTONE
           INVESTMENT              境外法人     5.03%       14,075,000             0
               LIMITED
    中国工商银行-博时精     境内非国有法
                                                3.93%       11,000,000             0
       选股票证券投资基金               人
    中海信托股份有限公司-
                              境内非国有法
    浦江之星 11 号集合资金                      0.44%        1,219,903             0
                                        人
                  信托计划
    百庚禹丰(北京)投资顾    境内非国有法
                                                0.38%        1,050,000     1,050,000   质押                 1,050,000
                问有限公司              人
    合众人寿保险股份有限     境内非国有法
                                                0.37%        1,047,712             0
    公司-万能-个险万能               人
                   赵秋怡       境内自然人      0.32%          887,082             0
    海通证券股份有限公司
                              境内非国有法
    客户信用交易担保证券                       0.31%          868,255             0
                                        人
                     账户
                     李亮       境内自然人      0.26%          715,000             0
    前十名无限售条件股东持股情况
                                                                                       股份种类及数量
                   股东名称                    持有无限售条件股份数量
                                                                            种类                    数量
       ORIENTAL KEYSTONE INVESTMENT
                                                            14,075,000   A股                               14,075,000
                             LIMITED
    中国工商银行-博时精选股票证券投资基
                                                            11,000,000   A股                               11,000,000
                                       金
    中海信托股份有限公司-浦江之星 11 号集合
                                                             1,219,903   A股                                1,219,903
                             资金信托计划
    合众人寿保险股份有限公司-万能-个险
                                                             1,047,712   A股                                1,047,712
                                     万能
                                     赵秋怡                    887,082   A股                                 887,082
    海通证券股份有限公司客户信用交易担保
                                                               868,255   A股                                 868,255
                                 证券账户
                                        李亮                   715,000   A股                                 715,000
    广发证券股份有限公司客户信用交易担保
                                                               658,618   A股                                 658,618
                                 证券账户
                                     贾丽娟                    646,896   A股                                 646,896
                                     吴秀容                    601,200   A股                                 601,200
                                               哈尔滨恒世达昌科技有限公司与 YU HENG INTERNATIONAL
    上述股东关联关系或(及)一致行动人的说     INVESTMENTS CORPORATION 属同一实际控制人控制,未知其他股东是
    明                                         否存在关联关系,也未知是否属于《上市公司持股变动信息披露管理办法》
                                               中规定的一致行动人。4
             哈尔滨誉衡药业股份有限公司                                                           2012 年半年度报告摘要(三)控股股东及实际控制人变更情况□ 适用 √ 不适用
                              四、董事、监事和高级管理人员情况(一)董事、监事和高级管理人员持股变动
                                                                                   其中:持有
                                            本期增持     本期减持                               期末持有
                              期初持股                              期末持股       限制性股
      姓名          职务                    股份数量     股份数量                               股票期权         变动原因
                              数(股)                              数(股)         票数量
                                              (股)       (股)                               数量(股)
                                                                                     (股)
    朱吉满       董事长              0              0           0              0           0            0    -
    王东绪       副董事长            0              0           0              0           0            0    -
                 董事、总经
    杨红冰                           0              0           0              0           0            0    -
                 理
                 董事、财务
    杨华蓉                           0              0           0              0           0            0    -
                 总监
                 董事、副总
    何利群                           0              0           0              0           0            0    -
                 经理
                 董事、董事
    于天巡                           0              0           0              0           0            0    -
                 会秘书
    赵中秋       独立董事            0              0           0              0           0            0    -
    董琦         独立董事            0              0           0              0           0            0    -
    徐小舸       独立董事            0              0           0              0           0            0    -
    白莉惠       监事                0              0           0              0           0            0    -
    程根强       监事                0              0           0              0           0            0    -
                 职工代表
    吴玉峰                           0              0           0              0           0            0    -
                 监事
                 历任董事、
    冷国庆                           0              0           0              0           0            0    -
                 副总经理
    张桂荣       历任董事            0              0           0              0           0            0    -
                 历任职工
    郑绛青                           0              0           0              0           0            0    -
                 代表监事
                                                五、董事会报告(一)主营业务分行业、产品情况表
                                                                                                                   单位:元
                                                    主营业务分行业情况
       分行业           营业收入         营业成本       毛利率(%)        营业收入比上   营业成本比上    毛利率比上年5
           哈尔滨誉衡药业股份有限公司                                                                2012 年半年度报告摘要
                                                                           年同期增减       年同期增减     同期增减(%)
                                                                             (%)            (%)
    医药制造       216,954,919.23      39,947,223.10           81.59%            68.18%           49.26%          2.33%
    医药代理        114,748,194.93     90,918,534.16           20.77%             -4.98%          -6.04%           0.9%
    医药研发及临
                      1,400,000.00       109,925.24            92.15%           -73.12%          -91.24%         16.25%
    床服务
                                                       主营业务产品情况
                                                                          营业收入比上     营业成本比上
                                                                                                           毛利率比上年
       分产品         营业收入          营业成本          毛利率(%)       年同期增减       年同期增减
                                                                                                           同期增减(%)
                                                                              (%)            (%)
    针剂产品       288,574,386.01      96,002,811.83           66.73%            36.08%            2.54%         10.88%
    口服产品         40,905,716.60     33,770,232.85           17.44%            13.75%           16.49%         -1.94%
    其他产品          2,223,011.55      1,092,712.58           50.85%            28.15%           18.93%          3.81%
    委托研发项目      1,000,000.00        91,925.24            90.81%           -74.09%          -92.41%         22.19%
    临床试验项目          400,000.00      18,000.00             95.5%           -70.37%          -59.45%         -1.21%毛利率比上年同期增减幅度较大的原因说明1、分行业分类中,医药研发及临床服务毛利率同期对比增幅16.25%,主要是因为研发项目因最终结算,本期确认的收入、成本未与进度匹配,导致本期毛利率较高。2、分产品分类中,针剂产品毛利率同期对比增幅10.88%,主要是受以下两方面因素影响:A、销售政策变化,部分产品价格提升;B、报告期产量增大,产品单位制造成本降低。委托研发项目毛利率同期对比增幅22.19%,原因同说明1。(二)主营业务分地区情况
                                                                                                                 单位:元
                   地区                                    营业收入                      营业收入比上年同期增减(%)
    华北地区                                                          48,187,806.84                              20.06%
    东北地区                                                          22,638,306.45                              27.86%
    华东地区                                                          99,556,996.87                              54.42%
    华中地区                                                          45,195,718.61                              30.66%
    华南地区                                                          37,021,000.74                               2.52%
    西南地区                                                          56,729,896.85                              48.52%
    西北地区                                                          23,773,387.80                              28.19%(三)主营业务及其结构发生重大变化的原因说明□ 适用 √ 不适用(四)主营业务盈利能力(毛利率)与上年相比发生重大变化的原因说明□ 适用 √ 不适用(五)利润构成与上年相比发生重大变化的原因分析√ 适用 □ 不适用与上年同期相比,有重大变化项目及原因如下:1、销售费用项目,主要是:销售模式变化,加大了市场投入,增加销售费用2,893.72万元;另外头孢米诺产品依据与日本明治制果株式会社签订了《协议书》、《技术合作合同》及《商标使用许可合同》,与珠海傲华医药科技有限公司签订《技术使用许可协议》相关条款规定,支付相应技术及商标使用费581.90万元。上年同期未发生这部分费用。6
           哈尔滨誉衡药业股份有限公司                                                                2012 年半年度报告摘要2、利息收入:报告期收到募集专户定期存款利息1,265.81万元,而上年同期无此事项,导致利息收入较上期增幅较大。3、投资收益项目:报告期利用自有闲置资金进行投资理财,已取得投资收益88.48万元,上年同期无此事项;原按权益法核算的公司,纳入合并范围,与上年相比减少投资亏损92.97万元。(六)募集资金使用情况1、募集资金使用情况对照表√ 适用 □ 不适用
                                                                                                                   单位:万元
    募集资金总额                                                 167,850   本报告
                                                                           期投入
                                                                                                                    2,669.56
    报告期内变更用途的募集资金总额                                         募集资
                                                                           金总额
    累计变更用途的募集资金总额                                             已累计
                                                                           投入募
                                                                                                                   67,527.42
    累计变更用途的募集资金总额比例                                         集资金
                                                                           总额
                                                                           截至期
                        是否已                                                         项目达                        项目可
                                 募集资                          截至期    末投资
                        变更项               调整后    本报告                          到预定    本报告   是否达     行性是
    承诺投资项目和超             金承诺                          末累计     进度
                        目(含                投资总    期投入                          可使用    期实现   到预计     否发生
        募资金投向               投资总                          投入金    (%)(3)
                        部分变               额(1)     金额                            状态日    的效益   效益       重大变
                                   额                            额(2)        =
                          更)                                                            期                            化
                                                                           (2)/(1)
    承诺投资项目
                                                                                       2012 年
                                 18,355.     20,672.   1,782.2   20,102.
    GMP 技改项目        否                                                 97.24%      05 月              否        否
                                     69          68          2       65
                                                                                       31 日
                                                                                       2013 年
                                 24,516.     24,516.             1,356.6
    异地扩建            否                             104.18                  5.53%   10 月              否        否
                                     27          27                    5
                                                                                       31 日
                                 42,871.     45,188.             21,459.
    承诺投资项目小计    -                              1,886.4             -           -                  -         -
                                     96          95                   3
    超募资金投向
                                                                                       2012 年
    购置空港 Max 企业                                            12,208.
                        否       13,758      13,758    783.15              88.73%      07 月              否
    园区房产                                                         12
                                                                                       31 日
    支付广州市新花城                                                                   2011 年
    生物科技有限公司    否           3,380    3,380                3,380       100%    09 月              是
    20%股权                                                                            30 日
                                                                                       2010 年
    对经纬医药进行增
                        否           9,820    9,820                9,820       100%    09 月              是
    资
                                                                                       17 日
    购买化合物 SX004                                                                   2011 年
    及其衍生药物美迪    否           6,500    6,500                4,460   68.62%      09 月              是
    替尼的所有权                                                                       30 日
                                                                                       2011 年
    对山东誉衡药业投             8,305.8     8,305.8
                        否                                         6,000   72.24%      06 月              是
    资                                 8           8
                                                                                       30 日
                                                                                       2011 年
    对山东竣博医药增
                        否           1,000    1,000                1,000       100%    06 月              是
    资
                                                                                       30 日7
           哈尔滨誉衡药业股份有限公司                                                         2012 年半年度报告摘要
    科研开发、同行业并
                                  73,014.    70,697.
    购、补充流动资金及   否                                           0         0%                否
                                      16         17
    其他
    归还银行贷款(如
                         -         9,200      9,200               9,200        100%   -   -       -        -
    有)
    补充流动资金(如
                         -                                                            -   -       -        -
    有)
                                  124,97     122,66              46,068.
    超募资金投向小计     -                             783.15              -          -           -        -
                                    8.04       1.05                  12
                                  167,85     167,85    2,669.5   67,527.
    合计                 -                                                 -          -           -        -
                                       0          0          6       42
                       GMP 技改项目、异地扩建项目因以下两方面因素导致募集资金项目实际投入金额未达到计划进
    未达到计划进度或
                       度:1、因募集资金到位时间晚于原预计时间;2、因将执行新版 GMP 导致原设计变更。
    预计收益的情况和
    原因(分具体项目)
    项目可行性发生重
    大变化的情况说明
                         √ 适用 □ 不适用
                         1、根据本公司第一届董事会第十五次会议及 2010 年第二次临时股东大会审议通过,利用募集资
                         金超额部分中 9,200.00 万元偿还银行借款。截止 2012 年 6 月 30 日已全部支付上述借款。
                         2、根据本公司第一届董事会第十五次会议及 2010 年第二次临时股东大会审议通过,利用募集资
                         金超额部分中 9,820 万元增加全资子公司哈尔滨誉衡经纬医药发展有限公司注册资本,截止 2012
                         年 6 月 30 日已全部支付上述款项。
                         3、根据本公司第一届董事会第十五次会议及 2010 年第二次临时股东大会审议通过,利用募集资
                         金超额部分中 13,758.00 万元用于购置北京分公司及研发中心办公用地及房屋,截止 2012 年 6 月
                         30 日,已经支付 12,208.12 万元。
    超募资金的金额、用   4、根据本公司第一届董事会第十八次会议及 2010 年第三次临时股东大会审议通过,利用募集资
    途及使用进展情况     金超额部分中 6,500 万元用于购买化合物 SX004 及其衍生药物美迪替尼的所有权,截止 2012 年 6
                         月 30 日,应支付上述款项 4,460 万,实际已经支付 4,460 万元。
                         5、根据本公司第一届董事会第二十次会议审议通过,利用募集资金超额部分中 3,380 万元用于购
                         买广州市新花城生物科技有限公司 20%的股权。截止 2012 年 6 月 30 日,应支付上述款项 3,380
                         万,实际已经支付 3,380 万元。
                         6、根据本公司第一届董事会第二十五次会议审议通过,利用募集资金超额部分中 1,000 万元用于
                         对山东竣博医药有限公司增资。截止 2012 年 6 月 30 日,应支付上述款项 1,000 万,实际已经支
                         付 1,000 万元。
                         7、根据本公司第一届董事会第二十五次会议审议通过,利用募集资金超额部分投资设立山东誉衡
                         药业有限公司。截止 2012 年 6 月 30 日,应支付上述款项 6,000 万,实际已经支付 6,000 万元。
                         □ 适用 √ 不适用
    募集资金投资项目
                         □ 报告期内发生 □ 以前年度发生
    实施地点变更情况
                         □ 适用 √ 不适用
    募集资金投资项目
                         □ 报告期内发生 □ 以前年度发生
    实施方式调整情况
                         √ 适用 □ 不适用
    募集资金投资项目
                         1、哈尔滨誉衡药业股份有限公司 GMP 技改项目 2,764.38 万元;
    先期投入及置换情
    况                   2、哈尔滨誉衡药业股份有限公司异地扩建项目 983.40 万元。
    用闲置募集资金暂     □ 适用 √ 不适用
    时补充流动资金情
    况8
           哈尔滨誉衡药业股份有限公司                                                        2012 年半年度报告摘要
    项目实施出现募集     □ 适用 √ 不适用
    资金结余的金额及
    原因
                         尚未使用的募集资金存放于招商银行哈尔滨分行黄河路支行募投专户及上海浦发银行哈尔滨分行
                         营业部募投专户,其中:
    尚未使用的募集资
                         招商银行哈尔滨分行黄河路支行,帐号 451902047910702,余额为 822,395,837.85 元;
    金用途及去向
                         上海浦发银行哈尔滨分行营业部,帐号 65010154700010237,余额为 221,192,022.86 元。
    募集资金使用及披
    露中存在的问题或     无
    其他情况2、变更募集资金投资项目情况表□ 适用 √ 不适用(七)董事会下半年的经营计划修改计划□ 适用 √ 不适用(八)对 2012 年 1-9 月经营业绩的预计2012 年 1-9 月预计的经营业绩情况:归属于上市公司股东的净利润为正值且不属于扭亏为盈的情形归属于上市公司股东的净利润为正值且不属于扭亏为盈的情形
    2012 年 1-9 月归属于上市公司股东的净利润
                                                                         0%     至                            50%
    变动幅度
    2012 年 1-9 月归属于上市公司股东的净利润
                                                                     7,550.5    至                        11,325.75
    变动区间(万元)
    2011 年 1-9 月归属于上市公司股东的净利润
                                                                                                    75,505,029.04
    (元)
    业绩变动的原因说明                         加强公司主要产品的市场开拓力度,加强管理,稳步提高企业盈利能力。(九)董事会对会计师事务所本报告期“非标准审计报告”的说明□ 适用 √ 不适用(十)公司董事会对会计师事务所上年度“非标准审计报告”涉及事项的变化及处理情况的说明□ 适用 √ 不适用9
        哈尔滨誉衡药业股份有限公司                                       2012 年半年度报告摘要
                                     六、重要事项(一)收购、出售资产及资产重组1、收购资产□ 适用 √ 不适用收购资产情况说明2、出售资产情况□ 适用 √ 不适用出售资产情况说明3、自资产重组报告书或收购出售资产公告刊登后,该事项的进展情况及对报告期经营成果与财务状况的影响□ 适用 √ 不适用(二)担保事项□ 适用 √ 不适用(三)非经营性关联债权债务往来是否存在非经营性关联债权债务往来□ 是 □ 否(四)重大诉讼仲裁事项□ 适用 √ 不适用(五)其他重大事项及其影响和解决方案的分析说明□ 适用 √ 不适用1、证券投资情况□ 适用 √ 不适用证券投资情况的说明2、持有其他上市公司股权情况□ 适用 √ 不适用10
        哈尔滨誉衡药业股份有限公司                                                       2012 年半年度报告摘要持有其他上市公司股权情况的说明3、报告期内资金被占用情况及清欠进展情况□ 适用 √ 不适用截止报告期末,上市公司未完成非经营性资金占用的清欠工作的,董事会提出的责任追究方案□ 适用 √ 不适用4、承诺事项履行情况上市公司及其董事、监事和高级管理人员、公司持股 5%以上股东及其实际控制人等有关方在报告期内或持续到报告期内的以下承诺事项√ 适用 □ 不适用
             承诺事项                       承诺人                承诺内容                  履行情况股改承诺收购报告书或权益变动报告书中所作承诺资产置换时所作承诺
                                                            公司发行前股东恒世达
                                                            昌、誉衡国际以及百庚禹
                                                            丰承诺:自公司股票上市
                                     恒世达昌、誉衡国际及   之日起三十六个月内,不
    发行时所作承诺                                                                      正在履行中
                                     百庚禹丰               转让或者委托他人管理
                                                            其持有的发行人股份,也
                                                            不由发行人回购其持有
                                                            的股份;
                                                            承诺如果公司 2005 年
                                                            度、2006 年度按照高新
                                                            技术企业税收优惠政策
                                                            所享受的减按 15%的税
                                                            率征收企业所得税的税
                                     恒世达昌以及朱吉满     收优惠被认定无效,本公
    其他对公司中小股东所作承诺                                                        正在履行中
                                     和白莉惠夫妇           司需要补缴税金、滞纳
                                                            金、罚金或承担其它赔偿
                                                            责任的,将由恒世达昌以
                                                            及朱吉满和白莉惠夫妇
                                                            向本公司予以全额补偿,
                                                            并承担连带责任。5、董事会本次利润分配或资本公积金转增预案□ 适用 √ 不适用6、其他综合收益细目
                                                                                                       单位:元
                           项目                                    本期发生额               上期发生额1.可供出售金融资产产生的利得(损失)金额减:可供出售金融资产产生的所得税影响前期计入其他综合收益当期转入损益的净额11
          哈尔滨誉衡药业股份有限公司                                                2012 年半年度报告摘要小计2.按照权益法核算的在被投资单位其他综合收益中所享有的份额减:按照权益法核算的在被投资单位其他综合收益中所享有的份额产生的所得税影响前期计入其他综合收益当期转入损益的净额小计3.现金流量套期工具产生的利得(或损失)金额减:现金流量套期工具产生的所得税影响前期计入其他综合收益当期转入损益的净额转为被套期项目初始确认金额的调整额小计4.外币财务报表折算差额减:处置境外经营当期转入损益的净额小计5.其他减:由其他计入其他综合收益产生的所得税影响前期其他计入其他综合收益当期转入损益的净额小计合计(六)报告期接待调研、沟通、采访等活动登记表
                                                                                   谈论的主要内容及提
    接待时间           接待地点          接待方式      接待对象类型    接待对象
                                                                                         供的资料
                                                                                   产品销售情况、研发方2012 年 06 月 19
                     北京分公司        实地调研       机构             信诚基金    向及新药进展,募投项日
                                                                                   目进展。
                                                                                   产品销售情况、研发方2012 年 06 月 19
                     北京分公司        实地调研       机构             国信证券    向及新药进展,募投项日
                                                                                   目进展。
                                              七、财务报告(一)审计意见半年报是否经过审计□ 是 √ 否(二)财务报表是否需要合并报表:√ 是 □ 否12
          哈尔滨誉衡药业股份有限公司                                 2012 年半年度报告摘要1、合并资产负债表编制单位: 哈尔滨誉衡药业股份有限公司
                                                                                    单位: 元
              项目                附注   期末余额                   期初余额
    流动资产:
       货币资金                               1,281,646,236.87           1,453,522,599.70
       结算备付金
       拆出资金
       交易性金融资产                           200,000,000.00
       应收票据                                       420,000.00                2,878,210.00
       应收账款                                     31,009,350.48               3,188,085.06
       预付款项                                 190,456,327.27             200,040,023.77
       应收保费
       应收分保账款
       应收分保合同准备金
       应收利息                                                                20,250,000.00
       应收股利
       其他应收款                                   96,639,054.24              66,997,538.18
       买入返售金融资产
       存货                                         66,081,678.92              72,473,723.73
       一年内到期的非流动资产
       其他流动资产
    流动资产合计                             1,866,252,647.78           1,819,350,180.44
    非流动资产:
       发放委托贷款及垫款
       可供出售金融资产
       持有至到期投资
       长期应收款
       长期股权投资                                  1,081,465.70               1,081,465.70
       投资性房地产
       固定资产                                 226,258,215.35             231,112,401.69
       在建工程                                 207,446,970.02             142,033,720.63
       工程物资
       固定资产清理                                                                 3,935.83
       生产性生物资产
       油气资产
       无形资产                                     66,038,715.38              53,397,731.35
       开发支出                                     24,950,698.09              25,024,418.04
       商誉                                         34,169,999.58              34,169,999.58
       长期待摊费用                                   738,650.36                1,197,706.55
       递延所得税资产                                3,224,171.70               4,882,051.45
       其他非流动资产13
          哈尔滨誉衡药业股份有限公司                      2012 年半年度报告摘要
    非流动资产合计                     563,908,886.18          492,903,430.82
    资产总计                          2,430,161,533.96       2,312,253,611.26
    流动负债:
       短期借款
       向中央银行借款
       吸收存款及同业存放
       拆入资金
       交易性金融负债
       应付票据                           2,750,700.00            7,200,500.00
       应付账款                          35,017,093.47           30,416,277.20
       预收款项                           2,184,297.89            2,184,297.89
       卖出回购金融资产款
       应付手续费及佣金
       应付职工薪酬                         724,040.11             949,659.87
       应交税费                          13,564,575.21            8,765,723.55
       应付利息
       应付股利
       其他应付款                        73,189,147.38           31,757,376.62
       应付分保账款
       保险合同准备金
       代理买卖证券款
       代理承销证券款
       一年内到期的非流动负债
       其他流动负债
    流动负债合计                       127,429,854.06           81,273,835.13
    非流动负债:
       长期借款                          27,500,000.00           30,000,000.00
       应付债券
       长期应付款
       专项应付款
       预计负债
       递延所得税负债                                             3,037,500.00
       其他非流动负债                       596,000.00             596,000.00
    非流动负债合计                      28,096,000.00           33,633,500.00
    负债合计                           155,525,854.06          114,907,335.13
    所有者权益(或股东权益):
       实收资本(或股本)               280,000,000.00          280,000,000.00
       资本公积                        1,508,368,180.53       1,508,368,180.53
       减:库存股
       专项储备
       盈余公积                          52,355,305.31           52,355,305.31
       一般风险准备
       未分配利润                       405,220,589.38          327,367,231.6314
          哈尔滨誉衡药业股份有限公司                                                2012 年半年度报告摘要
       外币报表折算差额
    归属于母公司所有者权益合计                                 2,245,944,075.22             2,168,090,717.47
       少数股东权益                                               28,691,604.68               29,255,558.66
    所有者权益(或股东权益)合计                               2,274,635,679.90             2,197,346,276.13负债和所有者权益(或股东权
                                                            2,430,161,533.96             2,312,253,611.26益)总计
    法定代表人:朱吉满                       主管会计工作负责人:杨华蓉               会计机构负责人:赵金宇2、母公司资产负债表
                                                                                                   单位: 元
              项目                附注                 期末余额                    期初余额
    流动资产:
       货币资金                                             1,147,892,108.38             1,276,562,458.86
       交易性金融资产                                         158,000,000.00
       应收票据                                                     420,000.00                 2,263,300.00
       应收账款                                                   29,689,996.01                1,862,686.39
       预付款项                                               167,908,460.03              173,310,707.74
       应收利息                                                                               20,250,000.00
       应收股利
       其他应收款                                                 53,828,806.31               49,843,273.54
       存货                                                       48,090,024.42               59,119,171.45
       一年内到期的非流动资产
       其他流动资产
    流动资产合计                                           1,605,829,395.15             1,583,211,597.98
    非流动资产:
       可供出售金融资产
       持有至到期投资
       长期应收款
       长期股权投资                                           351,519,890.16              291,519,890.16
       投资性房地产
       固定资产                                               209,238,631.96              212,840,827.75
       在建工程                                               159,490,950.82              102,922,574.33
       工程物资
       固定资产清理                                                                                3,935.83
       生产性生物资产
       油气资产
       无形资产                                                   27,455,133.47               22,820,251.31
       开发支出                                                    8,676,387.89                8,821,800.98
       商誉
       长期待摊费用                                                 502,396.38                  793,491.82
       递延所得税资产                                              1,368,605.12                2,703,875.45
       其他非流动资产15
           哈尔滨誉衡药业股份有限公司                                 2012 年半年度报告摘要
      非流动资产合计                             758,251,995.80             642,426,647.63
      资产总计                                 2,364,081,390.95           2,225,638,245.61
      流动负债:
        短期借款
        交易性金融负债
        应付票据                                      2,750,700.00               7,200,500.00
        应付账款                                     29,305,027.66              26,202,988.73
        预收款项
        应付职工薪酬                                   283,026.07                  -57,765.64
        应交税费                                     18,197,794.80               6,862,693.86
        应付利息
        应付股利
        其他应付款                                   68,418,732.67              10,857,204.22
        一年内到期的非流动负债
        其他流动负债
      流动负债合计                               118,955,281.20                 51,065,621.17
      非流动负债:
        长期借款
        应付债券
        长期应付款
        专项应付款
        预计负债
        递延所得税负债                                                           3,037,500.00
        其他非流动负债
      非流动负债合计                                          0.00               3,037,500.00
      负债合计                                   118,955,281.20                 54,103,121.17
      所有者权益(或股东权益):
        实收资本(或股本)                       280,000,000.00             280,000,000.00
        资本公积                               1,508,119,070.29           1,508,119,070.29
        减:库存股
        专项储备                                              0.00
        盈余公积                                     52,355,305.31              52,355,305.31
        未分配利润                               404,651,734.15             331,060,748.84
        外币报表折算差额
      所有者权益(或股东权益)合
                                               2,245,126,109.75           2,171,535,124.44计
    负债和所有者权益(或股东权
                                               2,364,081,390.95           2,225,638,245.61益)总计3、合并利润表
                                                                                     单位: 元
                 项目              附注   本期金额                   上期金额
    一、营业总收入                                  333,124,341.47             254,966,833.8816
             哈尔滨誉衡药业股份有限公司                         2012 年半年度报告摘要
        其中:营业收入                         333,124,341.47          254,966,833.88
               利息收入
               已赚保费
               手续费及佣金收入
    二、营业总成本                                239,574,710.11          177,728,443.97
        其中:营业成本                         130,976,786.86          124,786,075.12
               利息支出
               手续费及佣金支出
               退保金
               赔付支出净额
               提取保险合同准备金净额
               保单红利支出
               分保费用
               营业税金及附加                    4,266,651.16            2,882,974.97
               销售费用                         64,133,927.29           22,292,345.17
               管理费用                         55,650,119.89           31,622,827.79
               财务费用                        -15,720,917.10           -3,077,726.64
               资产减值损失                       268,142.01              -778,052.44
    加    :公允价值变动收益(损失以“-”号填列)
           投资收益(损失以
                                                  884,759.13              -929,676.65“-”号填列)
           其中:对联营企业和
                                                                          -929,676.65合营企业的投资收益
               汇兑收益(损失以“-”号填列)三、营业利润(亏损以“-”号
                                                94,434,390.49           76,308,713.26填列)
        加   :营业外收入                           27,326.02               43,170.00
        减   :营业外支出                         104,635.83              108,798.84
               其中:非流动资产处
                                                     3,935.83                8,798.84置损失四、利润总额(亏损总额以“-”
                                                94,357,080.68           76,243,084.42号填列)
        减:所得税费用                          17,067,676.91           12,359,124.66五、净利润(净亏损以“-”号
                                                77,289,403.77           63,883,959.76填列)
    其中:被合并方在合并前实现的净利润
        归属于母公司所有者的净
                                                77,853,357.75           63,883,959.76利润
        少数股东损益                              -563,953.98
    六、每股收益:                           --                      --
        (一)基本每股收益                               0.28                    0.23
        (二)稀释每股收益                               0.28                    0.2317
           哈尔滨誉衡药业股份有限公司                                                  2012 年半年度报告摘要七、其他综合收益
    八、综合收益总额                                                    77,289,403.77               63,883,959.76
    归属于母公司所有者的综
                                                                     77,853,357.75               63,883,959.76合收益总额
    归属于少数股东的综合收
                                                                       -563,953.98益总额本期发生同一控制下企业合并的,被合并方在合并前实现的净利润为:元。
    法定代表人:朱吉满                          主管会计工作负责人:杨华蓉               会计机构负责人:赵金宇4、母公司利润表
                                                                                                      单位: 元
                项目                 附注                 本期金额                    上期金额
    一、营业收入                                                     216,956,873.08              128,999,925.08
        减:营业成本                                                 45,819,537.26               32,633,323.07
            营业税金及附加                                            3,214,075.79                1,813,116.58
            销售费用                                                 47,488,348.86                8,820,612.17
            管理费用                                                 46,491,357.29               24,252,448.26
            财务费用                                              -13,872,061.44                 -2,929,554.17
            资产减值损失                                               164,853.10                   13,214.29
    加:公允价值变动收益(损失以“-”号填列)
            投资收益(损失以“-”
                                                                       585,197.63                52,015,859.10号填列)
         其中:对联营企业和合
                                                                                                   -929,676.65营企业的投资收益二、营业利润(亏损以“-”号
                                                                     88,235,959.85            116,412,623.98填列)
        加:营业外收入                                                  16,512.02                   57,794.48
        减:营业外支出                                                 103,935.83                  108,798.84
            其中:非流动资产处置
                                                                          3,935.83                    8,798.84损失三、利润总额(亏损总额以“-”
                                                                     88,148,536.04            116,361,619.62号填列)
        减:所得税费用                                               14,557,550.73                8,065,095.29四、净利润(净亏损以“-”号
                                                                     73,590,985.31            108,296,524.33填列)
    五、每股收益:                                              --                          --
        (一)基本每股收益                                                    0.26                        0.39
        (二)稀释每股收益                                                    0.26                        0.39六、其他综合收益
    七、综合收益总额                                                    73,590,985.31            108,296,524.335、合并现金流量表
                                                                                                      单位: 元18
           哈尔滨誉衡药业股份有限公司                                 2012 年半年度报告摘要
                 项目                   本期金额                    上期金额一、经营活动产生的现金流量:
        销售商品、提供劳务收到的现
                                                   370,489,807.82              292,385,262.73金
        客户存款和同业存放款项净增加额
        向中央银行借款净增加额
        向其他金融机构拆入资金净增加额
        收到原保险合同保费取得的现金
        收到再保险业务现金净额
        保户储金及投资款净增加额
        处置交易性金融资产净增加额
        收取利息、手续费及佣金的现金
        拆入资金净增加额
        回购业务资金净增加额
        收到的税费返还
        收到其他与经营活动有关的现
                                                    29,316,820.91               63,304,123.40金
    经营活动现金流入小计                              399,806,628.73              355,689,386.13
        购买商品、接受劳务支付的现
                                                   156,967,049.89              161,949,590.75金
        客户贷款及垫款净增加额
        存放中央银行和同业款项净增加额
        支付原保险合同赔付款项的现金
        支付利息、手续费及佣金的现金
        支付保单红利的现金
        支付给职工以及为职工支付的
                                                    32,228,807.91               21,149,191.60现金
        支付的各项税费                              50,866,856.14               40,788,983.04
        支付其他与经营活动有关的现
                                                    52,123,101.70               88,215,545.00金
    经营活动现金流出小计                              292,185,815.64              312,103,310.39
    经营活动产生的现金流量净额                        107,620,813.09               43,586,075.74二、投资活动产生的现金流量:
        收回投资收到的现金                         210,000,000.00
        取得投资收益所收到的现金                      884,759.13
    处置固定资产、无形资产和其
                                                        27,595.00                    1,625.00他长期资产收回的现金净额
    处置子公司及其他营业单位收到的现金净额
        收到其他与投资活动有关的现19
         哈尔滨誉衡药业股份有限公司                                 2012 年半年度报告摘要金
    投资活动现金流入小计                            210,912,354.13                    1,625.00
    购建固定资产、无形资产和其
                                                  99,795,535.26               58,443,152.98他长期资产支付的现金
      投资支付的现金                             419,900,000.00
      质押贷款净增加额
    取得子公司及其他营业单位支
                                                                               5,361,351.31付的现金净额
      支付其他与投资活动有关的现金
    投资活动现金流出小计                            519,695,535.26               63,804,504.29
    投资活动产生的现金流量净额                  -308,783,181.13                 -63,802,879.29三、筹资活动产生的现金流量:
      吸收投资收到的现金
    其中:子公司吸收少数股东投资收到的现金
      取得借款收到的现金
      发行债券收到的现金
      收到其他与筹资活动有关的现
                                                  32,908,144.94                2,463,260.99金
    筹资活动现金流入小计                             32,908,144.94                2,463,260.99
      偿还债务支付的现金                           2,500,000.00
    分配股利、利润或偿付利息支
                                                   1,120,643.05               70,187,966.09付的现金
    其中:子公司支付给少数股东的股利、利润
      支付其他与筹资活动有关的现
                                                       1,496.68金
    筹资活动现金流出小计                              3,622,139.73               70,187,966.09
    筹资活动产生的现金流量净额                       29,286,005.21              -67,724,705.10四、汇率变动对现金及现金等价物的影响
    五、现金及现金等价物净增加额                -171,876,362.83                 -87,941,508.65
      加:期初现金及现金等价物余
                                             1,453,522,599.70            1,538,322,600.66额
    六、期末现金及现金等价物余额                1,281,646,236.87            1,450,381,092.016、母公司现金流量表
                                                                                   单位: 元
               项目                   本期金额                    上期金额一、经营活动产生的现金流量:
      销售商品、提供劳务收到的现
                                                 233,045,916.65              158,475,570.78金
      收到的税费返还
      收到其他与经营活动有关的现
                                                   2,097,436.56                1,827,644.98金20
           哈尔滨誉衡药业股份有限公司                     2012 年半年度报告摘要
    经营活动现金流入小计                   235,143,353.21          160,303,215.76
        购买商品、接受劳务支付的现
                                         51,075,558.19           62,166,598.63金
        支付给职工以及为职工支付的
                                         19,482,546.93           13,671,377.54现金
        支付的各项税费                   37,898,730.14           26,709,193.20
        支付其他与经营活动有关的现
                                         26,572,365.39           14,820,129.77金
    经营活动现金流出小计                   135,029,200.65          117,367,299.14
    经营活动产生的现金流量净额             100,114,152.56           42,935,916.62二、投资活动产生的现金流量:
        收回投资收到的现金              140,000,000.00
        取得投资收益所收到的现金            585,197.63           52,945,535.75
    处置固定资产、无形资产和其
                                             27,595.00                1,625.00他长期资产收回的现金净额
    处置子公司及其他营业单位收到的现金净额
        收到其他与投资活动有关的现金
    投资活动现金流入小计                   140,612,792.63           52,947,160.75
    购建固定资产、无形资产和其
                                         44,439,867.77           51,554,518.34他长期资产支付的现金
        投资支付的现金                  367,900,000.00           75,380,000.00
    取得子公司及其他营业单位支
                                                                 75,380,000.00付的现金净额
        支付其他与投资活动有关的现金
    投资活动现金流出小计                   412,339,867.77          126,934,518.34
    投资活动产生的现金流量净额             -271,727,075.14         -73,987,357.59三、筹资活动产生的现金流量:
        吸收投资收到的现金
        取得借款收到的现金
        发行债券收到的现金
        收到其他与筹资活动有关的现
                                         62,908,144.94           12,463,260.99金
    筹资活动现金流入小计                    62,908,144.94           12,463,260.99
        偿还债务支付的现金
    分配股利、利润或偿付利息支
                                                                 70,187,966.09付的现金
        支付其他与筹资活动有关的现
                                         19,965,572.84           26,798,423.44金
    筹资活动现金流出小计                    19,965,572.84           96,986,389.53
    筹资活动产生的现金流量净额              42,942,572.10          -84,523,128.54四、汇率变动对现金及现金等价物的影响
    五、现金及现金等价物净增加额           -128,670,350.48        -115,574,569.5121
           哈尔滨誉衡药业股份有限公司                                                               2012 年半年度报告摘要
      加:期初现金及现金等价物余
                                                             1,276,562,458.86                           1,431,088,155.41额
    六、期末现金及现金等价物余额                                1,147,892,108.38                           1,315,513,585.907、合并所有者权益变动表本期金额
                                                                                                                单位: 元
                                                                      本期金额
                                                    归属于母公司所有者权益
             项目            实收                                                                               所有者
                                                                           一般    未分               少数股
                             资本       资本     减:库   专项    盈余                                          权益合
                                                                           风险    配利     其他      东权益
                             (或       公积     存股     储备    公积                                            计
                                                                           准备    润
                             股本)一、上年年末余额
      加:会计政策变更
           前期差错更正
           其他
                              280,0     1,508,                     52,35           327,3
                                                                                                      29,255,   2,197,34
    二、本年年初余额             00,00      368,1    0.00     0.00   5,305.    0.00   67,23     0.00
                                                                                                       558.66   6,276.13
                               0.00      80.53                        31            1.63
                                                                                    77,85
    三、本期增减变动金额(减                                                                             -563,95   77,289,4
                                                                                   3,357.
    少以“-”号填列)                                                                    75
                                                                                                         3.98      03.77
                                                                                    77,85
                                                                                                      -563,95   77,289,4
    (一)净利润                                                                      3,357.
                                                                                                         3.98      03.77
                                                                                       75(二)其他综合收益
                                                                                    77,85
                                                                                                      -563,95   77,289,4
    上述(一)和(二)小计                                                            3,357.
                                                                                                         3.98      03.77
                                                                                       75(三)所有者投入和减少资
                                0.00     0.00     0.00     0.00    0.00     0.00    0.00     0.00        0.00       0.00本1.所有者投入资本2.股份支付计入所有者权益的金额3.其他
    (四)利润分配                 0.00     0.00     0.00     0.00    0.00     0.00    0.00     0.00        0.00       0.001.提取盈余公积2.提取一般风险准备3.对所有者(或股东)的分配4.其他
    (五)所有者权益内部结转       0.00     0.00     0.00     0.00    0.00     0.00    0.00     0.00        0.00       0.001.资本公积转增资本(或股本)2.盈余公积转增资本(或股本)3.盈余公积弥补亏损22
           哈尔滨誉衡药业股份有限公司                                                               2012 年半年度报告摘要4.其他
    (六)专项储备1.本期提取2.本期使用(七)其他
                              280,0     1,508,                     52,35           405,2
                                                                                                      28,691,   2,274,63
    四、本期期末余额             00,00      368,1    0.00     0.00   5,305.           20,58
                                                                                                       604.68   5,679.90
                               0.00      80.53                        31            9.38上年金额
                                                                                                                单位: 元
                                                                      上年金额
                                                    归属于母公司所有者权益
             项目            实收                                                                               所有者
                                                                           一般    未分               少数股
                             资本       资本     减:库   专项    盈余                                          权益合
                                                                           风险    配利     其他      东权益
                             (或       公积     存股     储备    公积                                            计
                                                                           准备    润
                             股本)一、上年年末余额
    加:同一控制下企业合并产生的追溯调整
       加:会计政策变更
           前期差错更正
           其他
                              140,0     1,647,                     35,72           297,1
                                                                                                                2,120,74
    二、本年年初余额             00,00      868,1                    1,747.           52,52
                                                                                                                2,457.91
                               0.00      80.53                        62            9.76
                              140,0     -139,5                     16,63            30,21
    三、本期增减变动金额(减                                                                             29,255,   76,603,8
                              00,00      00,00                    3,557.           4,701.
    少以“-”号填列)            0.00       0.00                        69               87
                                                                                                       558.66      18.22
                                                                                   116,8
                                                                                                      -342,75   116,505,
    (一)净利润                                                                      48,25
                                                                                                         7.21     502.35
                                                                                    9.56(二)其他综合收益
                                                                                   116,8
                                                                                                      -342,75   116,505,
    上述(一)和(二)小计                                                            48,25
                                                                                                         7.21     502.35
                                                                                    9.56
    (三)所有者投入和减少资               500,0                                                         29,598,   30,098,3
                               0.00               0.00     0.00    0.00     0.00    0.00     0.00
    本                                     00.00                                                          315.87      15.871.所有者投入资本2.股份支付计入所有者权益的金额
                                        500,0                                                         29,598,   30,098,33.其他
                                        00.00                                                          315.87      15.87
                                                                   16,63           -86,63
                                                                                                                -70,000,
    (四)利润分配                0.00      0.00     0.00     0.00   3,557.    0.00   3,557.    0.00        0.00
                                                                                                                  000.00
                                                                      69               69
                                                                   16,63           -16,63
    1.提取盈余公积                                                  3,557.           3,557.
                                                                      69               692.提取一般风险准备
    3.对所有者(或股东)的                                                           -70,00                       -70,000,
    分配                                                                              0,000.                         000.0023
           哈尔滨誉衡药业股份有限公司                                                                        2012 年半年度报告摘要
                                                                                              004.其他
                              140,0     -140,0
    (五)所有者权益内部结转     00,00      00,00     0.00      0.00     0.00      0.00      0.00        0.00        0.00       0.00
                               0.00       0.00
                              140,0     -140,01.资本公积转增资本(或
                              00,00      00,00
    股本)                        0.00       0.002.盈余公积转增资本(或股本)3.盈余公积弥补亏损4.其他
    (六)专项储备1.本期提取2.本期使用(七)其他
                              280,0     1,508,                        52,35              327,3
                                                                                                               29,255,   2,197,34
    四、本期期末余额             00,00      368,1     0.00      0.00    5,305.     0.00     67,23        0.00
                                                                                                                558.66   6,276.13
                               0.00      80.53                           31               1.638、母公司所有者权益变动表本期金额
                                                                                                                         单位: 元
                                                                          本期金额
              项目               实收资                                                                                  所有者
                                            资本公        减:库存   专项储      盈余公            一般风     未分配
                               本(或股                                                                                  权益合
                                              积              股       备          积              险准备     利润
                                 本)                                                                                      计一、上年年末余额
       加:会计政策变更
           前期差错更正
           其他
                               280,000,     1,508,11                             52,355,3                     331,060,   2,171,53
    二、本年年初余额                                             0.00       0.00                         0.00
                                 000.00     9,070.29                                05.31                       748.84   5,124.44
    三、本期增减变动金额(减少                                                                                   73,590,9   73,590,9
    以“-”号填列)                                                                                                85.31      85.31
                                                                                                              73,590,9   73,590,9(一)净利润
                                                                                                                 85.31      85.31(二)其他综合收益
                                                                                                              73,590,9   73,590,9
    上述(一)和(二)小计            0.00          0.00         0.00       0.00          0.00           0.00
                                                                                                                 85.31      85.31
    (三)所有者投入和减少资本        0.00          0.00         0.00       0.00          0.00           0.00        0.00       0.001.所有者投入资本2.股份支付计入所有者权益的金额3.其他
    (四)利润分配                    0.00          0.00         0.00       0.00          0.00           0.00        0.00       0.001.提取盈余公积2.提取一般风险准备24
           哈尔滨誉衡药业股份有限公司                                                           2012 年半年度报告摘要3.对所有者(或股东)的分配4.其他
    (五)所有者权益内部结转          0.00       0.00        0.00      0.00       0.00      0.00        0.00        0.001.资本公积转增资本(或股本)2.盈余公积转增资本(或股本)3.盈余公积弥补亏损4.其他
    (六)专项储备                0.00       0.00        0.00      0.00       0.00      0.00        0.00        0.001.本期提取2.本期使用
    (七)其他                        0.00       0.00        0.00      0.00       0.00      0.00        0.00        0.00
                               280,000,   1,508,11                         52,355,3              404,651,    2,245,12
    四、本期期末余额                                         0.00      0.00
                                 000.00   9,070.29                            05.31                734.15    6,109.75上年金额
                                                                                                             单位: 元
                                                                    上年金额
              项目               实收资                                                                      所有者
                                          资本公      减:库存   专项储    盈余公     一般风      未分配
                               本(或股                                                                      权益合
                                            积            股       备        积       险准备        利润
                                 本)                                                                          计一、上年年末余额
       加:会计政策变更
           前期差错更正
           其他
                               140,000,   1,647,61                         35,721,7              251,358,    2,074,69
    二、本年年初余额                                         0.00
                                 000.00   9,070.29                            47.62                729.64    9,547.55
    三、本期增减变动金额(减少    140,000,   -139,500                         16,633,5              79,702,0    96,835,5
    以“-”号填列)                000.00     ,000.00                           57.69                 19.20       76.89
                                                                                                 166,335,    166,335,(一)净利润
                                                                                                   576.89      576.89(二)其他综合收益
                                                                                                 166,335,    166,335,上述(一)和(二)小计
                                                                                                   576.89      576.89
                                          500,000.                                                           500,000.
    (三)所有者投入和减少资本        0.00                   0.00      0.00       0.00      0.00        0.00
                                                00                                                                 001.所有者投入资本2.股份支付计入所有者权益的金额
                                          500,000.                                                           500,000.3.其他
                                                00                                                                 00
                                                                           16,633,5               -86,633,   -70,000,
    (四)利润分配                    0.00       0.00        0.00      0.00                 0.00
                                                                              57.69                 557.69     000.00
                                                                           16,633,5               -16,633,1.提取盈余公积
                                                                              57.69                 557.692.提取一般风险准备
    3.对所有者(或股东)的分                                                                        -70,000,   -70,000,
    配                                                                                                 000.00     000.0025
           哈尔滨誉衡药业股份有限公司                                                  2012 年半年度报告摘要4.其他
                               140,000,   -140,000
    (五)所有者权益内部结转                             0.00   0.00       0.00    0.00        0.00       0.00
                                 000.00     ,000.00
    1.资本公积转增资本(或股     140,000,   -140,000
    本)                            000.00     ,000.002.盈余公积转增资本(或股本)3.盈余公积弥补亏损4.其他
    (六)专项储备1.本期提取2.本期使用(七)其他
                               280,000,   1,508,11                  52,355,3            331,060,   2,171,53
    四、本期期末余额                                                               0.00
                                 000.00   9,070.29                     05.31              748.84   5,124.44(三)报表附注1、主要会计政策、会计估计的变更以及重大会计差错更正及其影响数(1)会计政策变更本报告期主要会计政策是否变更□ 是 √ 否(2)会计估计变更本报告期主要会计估计是否变更□ 是 √ 否(3)会计差错更正本报告期是否发现前期会计差错□ 是 √ 否2、合并报表合并范围发生变更的理由无3、被出具非标准审计报告,列示涉及事项的有关附注无
                                                                        哈尔滨誉衡药业股份有限公司
                                                                                        董事长:朱吉满
                                                                               二〇一二年八月十八日26